MEDIA WATCH: Viagra faces slew of healthy competitors
It has been a busy year for Pfizer, the maker of the ubiquitous erectile-dysfunction treatment, Viagra. The company spent the fifth birthday of its banner pill combating the first rivals to its worldwide monopoly. Bayer AG/GlaxoSmithKline's Levitra and Icos/Eli Lilly's Cialis have already started snatching up international market share (the latter awaits approval in the US). The coverage suggests that erectile dysfunction has a significantly bigger market than Viagra has tapped.
Sign in to continue
Need to activate your subscription?
Domain/Group Subscriptions
Click here >>
Individual Subscriptions
Click here >>
Need to activate your Subscription
Company Wide Subscriptions
Click here >>
UK Individual Subscribers
Click here >>